Press release: fda approves dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

Fda a pproves dupixent ® (dupilumab) as f irst t reatment for adult s and children aged 12 and older with e osinophilic e sophagitis

REGN Ratings Summary

REGN Quant Ranking